title: Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.
abstract: Human tumor-derived soluble NKG2D sMIC paralyzes the immune system through multiple pathways. Targeting soluble MIC with a nonblocking sMIC-neutralizing anti-MIC antibody effectuated and revamped endogenous innate and adoptive antitumor responses. Therapy induced regression of primary tumors and eliminated metastasis in preclinical models.
authors.affiliation: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA; Cancer Immunology Program, Hollings Cancer Center, Charleston, SC, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Wu
keywords: Cancer immunotherapy; NKG2D ligands; nonblocking sMIC-neutralizing anti-MIC antibody; soluble MIC